| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1025937928 |
| P356 | DOI | 10.1007/S00280-007-0500-1 |
| P698 | PubMed publication ID | 17522864 |
| P50 | author | David J. Sugarbaker | Q23304357 |
| Ravi Salgia | Q73567837 | ||
| P2093 | author name string | Beow Y Yeap | |
| Gautam Maulik | |||
| Hedy L Kindler | |||
| Raphael Bueno | |||
| Gavin J Gordon | |||
| Lipi Mukhopadhyay | |||
| Madhubalan Mani | |||
| P433 | issue | 4 | |
| P304 | page(s) | 549-558 | |
| P577 | publication date | 2007-05-24 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma | |
| P478 | volume | 61 |
| Q38760623 | A catalogue of treatment and technologies for malignant pleural mesothelioma |
| Q37703404 | A molecular targeting against nuclear factor-κB, as a chemotherapeutic approach for human malignant mesothelioma. |
| Q37070229 | Advances in the systemic therapy of malignant pleural mesothelioma |
| Q34340354 | Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity. |
| Q33999822 | Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma |
| Q28533736 | BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma |
| Q39748970 | Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types |
| Q35141369 | Chemotherapy and targeted therapies for unresectable malignant mesothelioma |
| Q52714599 | Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model. |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q48239512 | Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma |
| Q33503255 | Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target |
| Q34293068 | Investigational approaches for mesothelioma |
| Q37529848 | Malignant pleural mesothelioma: current treatments and emerging drugs. |
| Q38019747 | Malignant pleural mesothelioma: from the bench to the bedside. |
| Q38012566 | Molecular pathogenesis of malignant mesothelioma |
| Q37360580 | New diagnostic and molecular characteristics of malignant mesothelioma |
| Q37855667 | Novel targeted therapies and vaccination strategies for mesothelioma |
| Q36159154 | Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma |
| Q24170504 | Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells |
| Q47096168 | Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis |
| Q37873380 | Review on clinical trials of targeted treatments in malignant mesothelioma |
| Q37260408 | Systemic treatments for mesothelioma: standard and novel |
| Q34614482 | Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines |
| Q38347433 | The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance |
| Q36747341 | The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma. |
| Q37804621 | The unfolded protein response in lung disease |
| Q37734455 | Translational therapies for malignant pleural mesothelioma. |
| Q28534042 | Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy |
Search more.